[Hemorrhage caused by thrombocytopathies: new aspect of treatment (author's transl)].
Hemorrhage due to thrombocytopathies can in most cases be stopped by application of the homologous coagulation-active phospholipide complex Fibraccel, as shown in a study in which 78 patients suffering from various thrombocytopathies were checked. This effect is especially important in patients with immunothrombocytopathies which do not permit any thrombocyte substitution. Recalcification time and thromboelastogram should be normalised during Fibraccel treatment. In existing extravascular coagulation Fibraccel treatment is contraindicated, especially in cases of inadequate protection by heparin.
D001780:Blood Coagulation Tests; D001791:Blood Platelet Disorders / Q000150:complications* / Q000188:drug therapy; D006470:Hemorrhage / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D006801:Humans; D010743:Phospholipids / Q000009:adverse effects / Q000627:therapeutic use; D013916:Thrombelastography
D010743:Phospholipids
Thrombozytär bedingte Blutungen: neue Therapiemöglichkeiten